Comparative molecular analysis of colorectal cancer in Saudi Arabia: distinct genetic alterations and clinical features
By
Maha-Hamadien Abdulla
Jumanah Yousef Alshenaifi
Mansoor-Ali Vaali-Mohammed
Ahmad Zubaidi
Khayal Al Khayal
Noura S. Alhassan
Khalid Abdulrahman Al-Saleh
Omar Al Obeed
Scott Kopetz
May 1, 2026
Clinical Scorecard: Molecular Comparison of Colorectal Cancer in Saudi Arabia: Unique Genetic Changes and Clinical Characteristics
At a Glance
Category Detail
Condition Key Mechanisms Unique mutational profiles with reduced KRAS mutations (6.5%) and APC mutations (47.8%), increased TP53 mutations (50.0%). Target Population Care Setting
Key Highlights
Distinct mutation profiles in Saudi CRC patients compared to Western populations, with KRAS (6.5%) and APC (47.8%) mutations significantly lower. Guideline-Based Recommendations
Diagnosis
Management
Consider population-specific genetic markers for personalized treatment approaches, including targeted therapies based on mutation profiles. Monitoring & Follow-up
Risks
Patient & Prescribing Data
Therapeutic responses may differ due to unique mutation profiles, particularly in KRAS and APC.
Clinical Best Practices
Focus on genetic profiling to inform treatment strategies. Enhance public health initiatives, such as community awareness programs and screening campaigns, to improve early detection rates. References
